CVS Stock Analysis — CVS Health
Sector: Healthcare
AI Verdict
CVS trades at just 11.3x next year's earnings while analysts expect a 413.9% EPS surge — that's cheap for the growth on offer if the vertical integration moat delivers, but the rebound is a high bar to clear.
Competitive Moat
CVS Health combines a national pharmacy chain, a major health insurer (Aetna), and a large pharmacy benefits manager, creating a vertically integrated healthcare platform that locks in customers across the prescription, insurance, and care delivery chain. This integration gives CVS scale-driven cost advantages and makes it hard for competitors to replicate its breadth of services.
Summary
CVS's forward P/E of 11.3x reflects analyst expectations for a massive 413.9% EPS rebound after a weak earnings year.
Where It Stands
CVS has delivered a 25.03% 1-year return, sits at a neutral RSI of 56.8, and trades at 11.3x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 56.8 — Neutral
- Trailing P/E: 58.2x
- Forward P/E: 11.3x
- PEG Ratio: 0.14
- Earnings Growth: +4.1%
- Revenue Growth: +0.1%
- Market Cap: $104.0B
- Dividend Yield: 0.03%
- 1-Year Return: 25.03%
- 52-Week High: $85.15
- 52-Week Low: $58.35
Analyst Consensus
26 Buy · 7 Hold · 0 Sell (33 analysts)
Bull Case
With analysts forecasting 413.9% EPS growth and a forward P/E of just 11.3x, the stock is cheap for the rebound expected if integration efficiencies materialize.
Bear Case
If the forward P/E re-rates up to the sector median of 22x without the forecasted earnings surge, investors could face a sharp correction from current levels.
Catalyst to Watch
Watch for next quarter's EPS report — a miss on the 413.9% growth expectation would undermine the low valuation thesis.